Please login to the form below

Not currently logged in

Pfizer expands generic portfolio

Pfizer has entered into a series of agreements to commercialise several products that have lost market exclusivity in the US and Europe

Pfizer has entered into a series of agreements with India-based, Aurobindo to commercialise several products that have lost market exclusivity in the US and Europe.

The commercialisation will be managed by Pfizer's Established Product Business Unit, which has global annual sales of $10bn. The financial terms of the deal have not been disclosed.

The agreement relates to solid oral dose medicines that are no longer protected by patents and includes 39 products in the US, 20 in Europe including a further 11 in France, covering a broad range of therapeutic areas such as central nervous system disorders and cardiovascular disease. In addition, Pfizer has acquired the rights to 12 sterile injectable antibiotic products in the US and Europe.

"We will dramatically change Pfizer's Established Products portfolio to an engine of positive growth. These agreements represent solid, measurable progress, and a strong commitment to achieve our growth objectives," said David Simmons, president and general manager of Pfizer's Established Products Business Unit.

These agreements build on a five-product US deal agreed between the companies in July 2008.

4th March 2009


Featured jobs

Subscribe to our email news alerts


Add my company

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...